Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers December 18, 2018
Pharmacy Choice - News - U.S. Pharmaceutical Industry - December 18, 2018

Pharmacy News

 U.S. Pharmaceutical Industry
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

12/18/18 - Bridge Biotherapeutics Announces FDA Clearance of IND for its BBT-877, an Autotaxin Inhibitor for IPF [Sport360]
Bridge Biotherapeutics Inc., a clinical stage biotech company headquartered in Seongnam, South Korea and a tenant company of JLABS@ TMC in Houston, Texas, announced that the Investigational New Drug application for BBT-877, a potent best-in-class drug candidate for Idiopathic Pulmonary Fibrosis, has been cleared by the US Food and Drug Administrati
12/18/18 - Celltrion/Tevas Herceptin biosimilar approved in US [Syrian Arab News Agency]
The FDA has approved Celltrion and Tevas biosimilar of Roches breast cancer drug Herceptin, the second potential competitor to the cancer blockbuster in the US. All three are threatened by biosimilar competition, although Mylan and Celltrion will be unable to launch Herceptin in the US until the patent expires. Celltrion and Teva began an exclusive
12/18/18 - Curetis Subsidiary Ares Genetics Teams Up with Leading Global Pharma Company in Fight Against Antibiotic Resistance
Strategic collaboration agreement with Sandoz to develop digital anti-infectives platform Collaboration leverages Ares Genetics antibiotic resistance database ARESdb Short-term focus on repurposing existing antibiotics to treat infections with multi drug resistant pathogens Vienna, Austria, Holzgerlingen, Germany and Amsterdam, The...
12/18/18 - Delivering Results: After Portman-Led Investigation, Drug Manufacturer Lowers Prices for Opioid Overdose Reversal Drug
Rob Portman, R- Ohio, issued the following news release:. After a year-long investigation, Senator Portman, the chair of the Senate Permanent Subcommittee on Investigations, issued a report on November 18 into why kaleo increased the price of its naloxone drug EVZIO from $575 to $4,100 in just two-and-a-half years- all despite recommendations from
12/18/18 - DelSiTech and Innovare Sign Licensing Agreement for the Development of a Long Acting HIV Therapy
Under the terms of the agreement, Innovare will use DelSiTech's technology on its peptide membrane fusion inhibitor, targeting the envelope protein of human immunodeficiency virus-1. "This agreement with Innovare follows an already successful and long-lasting collaboration on this peptide", said Dr. "Using DelSiTech's platform, we have developed
12/18/18 - Global Personalized Medicine Market Set for Rapid Growth to Reach Around $3466 Mn by 2024: Global personalized medicine market expected to generate revenue of around USD 3466 million by 2024, growing at a CAGR of around 11.9% between 2018 and 2024. P
Sarasota, FL 12/18/2018 Zion Market Research has published a new report titled "Personalized Medicine Market by Therapeutic Area, by Application, by End-User, and by Technology: Global Industry Perspective, Comprehensive Analysis, and Forecast, 2017 2024". According to the report, the global personalized medicine market was valued at appro
12/18/18 - Global Stem Cell Therapy Market 2018 Industry Analysis, Size, Share, Strategies and Forecast to 2025
"Global Stem Cell Therapy Industry" New Study On 2018-2025 Stem Cell Therapy Market Global Key Player, Demand, Growth, Opportunities and Analysis Forecast Added to Wise Guy Reports Database. New Study On "2018-2025 Stem Cell Therapy Market Global Key Player, Demand, Growth, Opportunities and Analysis Forecast" Added to Wise Guy Reports Databa
12/18/18 - Herbal Extracts Market Analysis 2018 to 2023 | Industry Challenges, Key Vendors, Gross Margin, Drivers, Trend and Forecast
"\"\ "Herbal Extracts Market Worldwide Research Report\" " Herbal Extracts Market Worldwide Research Report by Ingredient, Application and Region Forecast till 2023. Pharmaceutical industry, especially herbal dietary supplements, is gaining acceptance in developed economies, which, in turn, would accelerate the sales of herbal extract during the fo
12/18/18 - Mallinckrodt plans spin-off biz for generics, APIs, and Amitiza [Sudan Tribune]
Under the Mallinckrodt name, its specialty generics business will be spun-off to shareholders and listed on the New York Stock Exchange. The inclusion of the Amitiza product in the non-promoted assets to be spun off brings added manufacturing facilities and employees in Japan, and diversified revenues further, according to Mallinckrodt.
12/18/18 - MarketResearchReports.com: Diabetic Foot Ulcer Market and Drug Pipeline Analysis - Forecast to 2025; New Report Launched
Diabetic Foot Ulcer Pipeline Analysis report gives comprehensive insights on the various drugs being developed for the treatment of DFU. The report covers all the drugs that are in various phases of development. The pipeline focuses on novel pharmacologic drugs and regenerative medicines covering, antibodies, stem cell therapies, recombinant protei
12/18/18 - Nature's Answer? Brocco-Glutathione Wins Better Nutrition Magazine Best of Supplements Award; Nature's Answer Innovative Brocco-Glutathione Awarded in the Anti-aging Category of Better Nutrition Magazine in 2018
Hauppauge, NY Serving as one of America's largest and oldest manufacturers of top-quality nutritional supplements for almost 50 years, Nature's Answer's family-owned and operated brand takes home the Best of Supplements award from Better Nutrition magazine featuring Brocco-Glutathione in the anti-aging category. In addition to using Setria ...
12/18/18 - New Animal Drugs; Approval of New Animal Drug Applications; Changes of Sponsorship; Change of a Sponsor's Name and Address
Agency: " Food and Drug Administration, HHS." FOR FURTHER INFORMATION CONTACT: George K. Haibel, Center for Veterinary Medicine, Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 240-402-5689, george.haibel@fda.hhs.gov. These public documents may be seen in the office of the Dockets Management Staff, Food and Drug Administration
12/18/18 - PEIA members air concerns, wishes at Finance Board public hearing [The Dominion Post, Morgantown, W.Va.]
Dec. 18 MORGANTOWN The Public Employees Insurance Agency Finance Board came to Morgantown Monday evening for a public hearing. "We expect you to have a moral and ethical stance of some nature that recognizes the value of the human beings in West Virginia.... We are the people of West Virginia.
12/18/18 - Rentschler Biopharma SE to Purchase U.S. Manufacturing Site from Shire plc [Syrian Arab News Agency]
Rentschler Biopharma SE, a leading contract development and manufacturing organization for biopharmaceuticals, announced today that the Company has signed an agreement to purchase a manufacturing facility from an affiliate Shire plc in Milford near Boston, MA, USA.. The development and manufacturing site will be leveraged as a CDMO by Rentschler...
12/18/18 - Sophiris Bio Provides Updates on Phase 2b Localized Prostate Cancer Trial [T-break Tech (Middle East)]
Sophiris Bio Inc., a biopharmaceutical company studying topsalysin, a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients with urological diseases, today provides an update from its Phase 2 b study of topsalysin for localized prostate cancer, including top-line safety and biopsy results from the patient
12/18/18 - UFI License and Validation Services
Office Address: Department of Health and Human Services; Food and Drug Administration; Office of Acquisitions and Grants Services- Rockville; 4041 Powder Mill Road Beltsville MD 20705. Office of Acquisitions and Grants Services- Rockville. Pre-Solicitation Notice of Sole Source Intent: The Food and Drug Administration intends to award a five- year
12/17/18 - 2018 and Beyond: Australia Pharmaceutical & Healthcare Market Trends & Outlook Study to 2025 - ResearchAndMarkets.com
Spending on medicines and healthcare in Australia witnessed steady growth in 2017, reflecting strong potential for new medicine development, infrastructure building and new entry/expansion opportunities. This report focuses its attention on pharmaceutical market in Australia and presents market trends, drivers and challenges facing the R&D...
12/17/18 - 40 Stocks Moving In Monday's Mid-Day Session
Gainers Diffusion Pharmaceuticals Inc. shares rose 65.1 percent to $4.7225 after the US Patent Office awarded the company exclusive rights for the use of its TSC drug in conjunction with tPA for stroke treatment. Synergy Pharmaceuticals Inc. climbed 34.2 percent to $0.1073 after Health Canada accepted Cipher Pharmaceuticals' new drug submission for
12/17/18 - Acer Therapeutics Appoints Salma Jutt as Chief Commercial Officer
Acer Therapeutics Inc., a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and ultra-rare diseases with critical unmet medical need, today announced that it has appointed Salma Jutt as Chief Commercial Officer. If EDSIVO? is approved by the FDA for the treatment of vascular Ehler
12/17/18 - Achillion Reports Positive Interim Data for ACH-4471 Phase 2 Trials and Provides Clinical Development Strategy Update
Achillion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement mediated disorders, today reported interim results for the Company s Phase 2 trials of its first-generation oral factor D inhibitor, ACH-4471, as well as Phase 1 pharmacokinetics and po
12/17/18 - Aclaris Therapeutics Provides Update on Oral and Topical JAK 1/3 Inhibitor Clinical Trials
Aclaris Therapeutics, Inc., a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in dermatology, both aesthetic and medical, and immunology, today provided updated data from three clinical trials for ATI-502, an investigational topical Janus
12/17/18 - AG Laxalt Touts Accomplishments of Career Public Servants and Thanks Nevada Stakeholders for the Opportunity to Serve
Nevada Attorney General Adam Paul Laxalt issued the following news release:. On January 5, 2015, Adam Paul Laxalt was sworn in as Nevada's 33rd attorney general, at the time making him the youngest attorney general in the nation. *initiated a working group to reduce Nevada's decades-in-the-making sexual assault kit backlog of nearly 8,000 untested
12/17/18 - Alder BioPharmaceuticals Reports Inducement Grant under Nasdaq Listing Rule 5635(4)
BOTHELL- Alder BioPharmaceuticals, Inc., a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today reported that the Compensation Committee of Alder's Board of Directors granted a non-qualified stock option to purchase an aggregate of 270,000 shares of Alder's common stock to Carlos E. Campo
12/17/18 - Alimera Sciences Announces Pricing Approval For ILUVIEN(R) in the U.A.E.
The U.A.E. becomes the first country in the Middle East to obtain pricing approval. ATLANTA, GA/ ACCESSWIRE/ December 17, 2018/ Alimera Sciences, Inc., a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that pricing approval had been received for ILUVIEN from the United Arab Emirates Minist
12/17/18 - Alkermes and Biogen Announce Submission of a New Drug Application to U.S. Food and Drug Administration for Diroximel Fumarate in Multiple Sclerosis
DUBLIN and CAMBRIDGE, Mass., Dec. 17, 2018/ PRNewswire/ Alkermes plc and Biogen Inc. today announced that Alkermes has submitted a New Drug Application to the U.S. Food and Drug Administration for diroximel fumarate, a novel oral fumarate in development for the treatment of relapsing forms of multiple sclerosis. Alkermes is seeking approval of di
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2018 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2018 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415